[HTML][HTML] Broad action of Hsp90 as a host chaperone required for viral replication

R Geller, S Taguwa, J Frydman - … et Biophysica Acta (BBA)-Molecular Cell …, 2012 - Elsevier
Viruses are intracellular pathogens responsible for a vast number of human diseases. Due
to their small genome size, viruses rely primarily on the biosynthetic apparatus of the host for …

Epigenetics as a therapeutic target in breast cancer

R Connolly, V Stearns - Journal of mammary gland biology and neoplasia, 2012 - Springer
Epigenetics refers to alterations in gene expression due to modifications in histone
acetylation and DNA methylation at the promoter regions of genes. Unlike genetic mutations …

Immunoliposomes

E Paszko, MO Senge - Current medicinal chemistry, 2012 - ingentaconnect.com
Since their discovery by Bangham about 50 years ago, liposomes have become promising
tools in drug delivery systems. This has increased the therapeutic index of many drugs, and …

AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches

MA Hatlen, L Wang, SD Nimer - Frontiers of medicine, 2012 - Springer
The AML1-ETO fusion transcription factor is generated by the t (8; 21) translocation, which is
present in approximately 4%–12% of adult and 12%–30% of pediatric acute myeloid …

Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in …

B Ramaswamy, W Fiskus, B Cohen… - Breast cancer research …, 2012 - Springer
In preclinical models, the histone deacetylase inhibitor vorinostat sensitizes breast cancer
cells to tubulin-polymerizing agents and to anti-vascular endothelial growth factor-directed …

HDAC modulation and cell death in the clinic

C Dell'Aversana, I Lepore, L Altucci - Experimental cell research, 2012 - Elsevier
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are two opposing
classes of enzymes, which finely regulate the balance of histone acetylation affecting …

Epigenetics modifications and therapeutic prospects in human thyroid cancer

MG Catalano, N Fortunati, G Boccuzzi - Frontiers in Endocrinology, 2012 - frontiersin.org
At present no successful treatment is available for advanced thyroid cancer, which
comprises poorly differentiated, anaplastic, and metastatic or recurrent differentiated thyroid …

[PDF][PDF] The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines

MG Kim, JH Pak, WH Choi, JY Park… - Journal of …, 2012 - synapse.koreamed.org
Objective: To investigate the relationship between cisplatin resistance and histone
deacetylase (HDAC) isoform overexpression in ovarian cancer cell lines. Methods …

Sensitization of tumor cells by targeting histone deacetylases

P Perego, V Zuco, L Gatti, F Zunino - Biochemical pharmacology, 2012 - Elsevier
Epigenetic mechanisms may contribute to drug resistance by interfering with tumor growth
regulatory pathways and pro-apoptotic programs. Since gene expression is regulated by …

A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL

JJ Hwang, YS Kim, T Kim, MJ Kim, IG Jeong… - Investigational new …, 2012 - Springer
We synthesized a novel hydroxamate-based pan-histone deacetylase inhibitor (HDACI),
CG200745 {(E)-2-(Naphthalen-1-yloxymethyl)-oct-2-enedioic acid 1-[(3-dimethylamino …